SERA PROGNOSTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sera Prognostics, Inc. on January 7, 2026. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Salt Lake City, Utah. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the publication of clinical study results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a scientific publication event rather than financial performance data.
Material Changes
The primary material event is the publication of the results of the "PRIME" study (Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcomes) in the Pregnancy Journal. The Company announced these results via a press release dated January 7, 2026.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The PRIME study results are scheduled to be discussed during a fireside chat hosted by Jefferies on January 9, 2026, at 8:30 am ET.
- Disclosure Status: The information contained in this Item 7.01 and the accompanying press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as required by law.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data points from the PRIME study.
- Confirm the date and time of the Jefferies fireside chat (January 9, 2026, 8:30 am ET) to access management commentary.
- Review the publication in the Pregnancy Journal at the provided URL for peer-reviewed details.
- Note that this filing contains no financial statements or updated financial guidance.